Abstract
Management of chronic pain with opioids is a common practice. Because of the addictive potential of these medications, strict monitoring to ensure compliance is enforced, including routine urine drug tests. Prior to prescribing opioids, medications are metabolized via cytochrome P450 enzymes should be taken into account by care providers. Such medications may need to be discontinued or their doses adjusted for maximal efficacy of pain management regimen. Genetic variation also plays a significant role in metabolism of these medications. Understanding these processes is crucial for physicians who prescribe opioids and clinical toxicologists who interpret the drug test results of patients.
Original language | English (US) |
---|---|
Title of host publication | Toxicology Cases for the Clinical and Forensic Laboratory |
Publisher | Elsevier |
Pages | 351-353 |
Number of pages | 3 |
ISBN (Electronic) | 9780128158463 |
ISBN (Print) | 9780128163733 |
DOIs | |
State | Published - Jan 1 2020 |
Keywords
- Chronic pain
- addiction
- cytochrome P450 enzymes
- genetic variation
- opioids
- toxicology
- urine drug tests
ASJC Scopus subject areas
- General Medicine